Barinthus Biotherapeutics plc Listed for High Court Scheme Hearing (CR-2025-006388)
On 1 September 2026 at 10:30am, clinical-stage biopharmaceutical entity Barinthus Biotherapeutics plc is scheduled to appear before the High Court of Justice in Court 9 of the Rolls Building. The hearing, listed under case reference CR-2025-006388 in the Insolvency and Companies Court, concerns a scheme of arrangement under Part 26 of the Companies Act 2006.
Hearing details
| Attribute | Detail |
| --- | --- |
| Case Number | CR-2025-006388 |
| Court | Insolvency and Companies Court (High Court of Justice) |
| Hearing Date & Time | 1 September 2026 at 10:30am |
| Hearing Venue | Court 9, The Rolls Building, London |
| Case Type | Scheme of Arrangement |
| Subject Entity | Barinthus Biotherapeutics plc |
| Registration Number | 13282620 |
Company snapshot
Barinthus Biotherapeutics plc (company registration number 13282620) was incorporated on 22 March 2021. Its registered office is located at 3rd Floor 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, as registered on the official Companies House register.
The business operates as a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for autoimmune and inflammatory diseases within the immunology and inflammation sector, as well as infectious diseases and oncology. Its primary research and development pipeline utilizes proprietary SNAP-TI platform and viral vector platform technologies (ChAdOx and MVA). As is standard for clinical-stage biotechnology developers, the entity does not currently report direct commercial product sales or manufacturing revenues.
According to the latest statutory financial statements filed for the accounting period ended 31 December 2024, Barinthus Biotherapeutics plc reported net assets of £24,400,000 and an average employee headcount of 123. The independent auditor's report returned an unqualified audit opinion with no going concern modification or statutory audit flag.
Directors and ownership
Public register records indicate that the board consists of executive and non-executive directors overseeing biopharmaceutical development, corporate strategy, and compliance. As a public limited company, equity ownership is distributed across institutional and market shareholders, subject to regulatory notification thresholds under UK market conduct rules. Details of individual directors, secretarial appointments, and persons with significant control filings remain accessible via Companies House statutory updates.
Recent filings and Gazette activity
A review of official statutory publications confirms no active winding-up petitions or formal insolvency actions listed in The Gazette. The current High Court listing under case number CR-2025-006388 pertains to a solvent corporate reorganisation governed by Part 26 of the Companies Act 2006.
Prior statutory filings submitted to Companies House include the annual audited accounts for the period ended 31 December 2024, annual confirmation statements, and statutory notifications regarding changes in officer details and registered office addresses.
What this means for suppliers, creditors and counterparties
A scheme of arrangement is a statutory mechanism under UK company law that enables a company to make a compromise or arrangement with its shareholders or creditors. Unlike compulsory liquidation matters supervised by the Insolvency Service, a scheme hearing does not signify commercial failure or insolvency. Schemes are regularly deployed by solvent public entities to effect group reorganisations, holding company restructurings, equity capital adjustments, or recommended corporate acquisitions.
Corporate intelligence professionals and credit managers reviewing trading counterparties listed in court proceedings should apply a structured evaluation procedure:
1. Verify court listing classification: Differentiate between solvent corporate schemes under Part 26, restructuring plans under Part 26A, and creditor-led winding-up petitions.
2. Review registered security interests: Perform a company charge check to confirm whether fixed or floating charges affect key intellectual property or balance sheet assets.
3. Assess balance sheet position: Review liquid assets, R&D expenditure commitments, and working capital ratios relative to existing supplier payables.
4. Monitor court list updates: Check the High Court order on the official roll to confirm whether the court sanctions the scheme or directs an adjournment.
5. Automate tracking: Set up free company monitoring to receive automatic alerts when post-hearing orders or statutory filings are lodged at Companies House.
Illustrative scenario: Counterparty assessment during corporate schemes
In a comparable biopharmaceutical reorganisation, a specialized clinical research provider supplying laboratory services received notification of a High Court company cause listing. By reviewing public court records and statutory filings, the credit risk team verified that the proceeding was a solvent equity restructuring scheme rather than an enforcement action. The supplier maintained regular trade payment terms while setting up automated monitoring to verify the final order registration.
How to investigate further
To track updates on this High Court listing, legal advisers and risk analysts can consult the daily list published on today's cause list. Counterparties evaluating broader corporate portfolios can conduct a comprehensive winding up petition search across UK registered entities to identify any pending court actions or insolvency filings.
FAQ
What is a scheme of arrangement under Part 26 of the Companies Act 2006?
A scheme of arrangement is a statutory, court-sanctioned procedure that allows a company to reach an agreement with its members or creditors regarding corporate reorganisations, debt restructurings, or group takeovers. Once approved by the requisite majorities and sanctioned by the court, it binds all affected parties.
Does a High Court scheme hearing indicate that a company is insolvent?
No. Schemes of arrangement under Part 26 are routinely used by solvent public and private entities to execute corporate restructurings, equity reorganisations, or recommended acquisitions. It is distinct from compulsory liquidation or insolvency administration.
How can creditors determine if a court scheme affects trade payables?
Suppliers and creditors should review the scheme documentation and circulars issued to voting classes. If general trade creditors are not identified as an affected class within the scheme terms, standard trade obligations remain payable according to existing commercial contracts.
What happens after the High Court sanctions a scheme?
Following court sanction, a formal court order is issued by the judge. The scheme of arrangement becomes legally binding once an official copy of the court order is filed with the Registrar of Companies at Companies House.
Disclaimer
This report summarises entries on the published court cause list. Presentation of a petition is not a determination of insolvency; the outcome is a matter for the court. Companies believing they are named incorrectly should email contact@corp-intel.co.uk.